Low-dose vigabatrin (γ-vinyl GABA)-induced damage in the immature rat brain

Experimental Neurology

Volumn 144, Issue 2, 1997, Pages 400-405

  Sidhu, Ranjinder S ^a   Del Bigio, Marc R ^a   Tuor, Ursula I ^a   Seshia, Shashikant S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTOSIS; BRAIN INJURY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; EPILEPSY; FRONTAL CORTEX; NERVE FIBER DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; WHITE MATTER;

EID: 0031128129     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6412     Document Type: Article

References (35)

1. Aicardi J., Mumford J. P., Dumas C., Wood S. Vigabatrin as initial therapy for infantile spasms: A European retrospective study. Epilepsia. 37:1996;638-642.
2. Aperia A., Herin P. Development of glomerular perfusion rate and nephron filtration rate in rats 17-60 days old. Am. J. Physiol. 228:1975;1319-1325.
3. Appleton R. E. Treatment of childhood epilepsy. Pharmacol. Ther. 67:1995;419-431.
4. Ben-Ari Y., Cherubini E., Corradetti R., Gaiarsa J. L. Giant synaptic potentials in immature rat CA3 hippocampal neurones. J. Physiol. 416:1989;303-325.
5. Brody B. A., Kinney H. C., Kloman A. S., Gilles F. H. Sequence of central nervous system myelination in human infancy. I. An autopsy study of myelination. J. Neuropathol. Exp. Neurol. 46:1987;283-301.
6. Butler W. H. The neuropathology of vigabatrin. Epilepsia. 30:1989;S15-S17.
7. Butt A. M., Tutton M. Response of oligodendrocytes to glutamate and gamma-aminobutyric acid in the intact mouse optic nerve. Neurosci. Lett. 146:1992;108-110.
8. Cannon D. J., Butler W. H., Mumford J. P., Lewis P. J. Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J. Child Neurol. 6:1991;S17-S24.
9. Choi E. Y., Jang S. H., Choi S. Y. Human brain GABA transaminase is immunologically distinct from those of other mammalian brains. Neurochem. Int. 28:1996;597-600.
10. 2+. J. Neurosci. 7:1987;1384-1400.
11. Cowan W. M., Fawcett J. W., O'Leary D. D., Stanfield B. B. Regressive events in neurogenesis. Science. 225:1984;1258-1265.
12. Davison A. N., Dobbing J. Myelination as a vulnerable period in brain development. Br. Med. Bull. 22:1966;40-44.
13. Durham S. L., Hoke J. F., Chen T. M. Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. Drug Metab. Dispos. 21:1993;480-484.
14. Ferrie C. D., Robinson R. O., Panayiotopoulos C. P. Psychotic and severe behavioural reactions with vigabatrin: A review. Acta Neurol. Scand. 93:1996;1-8.
15. Gibson J. P., Yarrington J. T., Loudy D. E., Gerbig C. G., Hurst G. H., Newberne J. W. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol. Pathol. 18:1990;225-238.
16. Graeber M. B., Kreutzberg G. W. Delayed astrocyte reaction following facial nerve axotomy. J. Neurocytol. 17:1988;209-220.
17. Gram L., Klosterkov P., Dam M. Gamma-vinyl GABA: A double-blind placebo controlled trial in partial epilepsy. Ann. Neurol. 17:1985;262-266.
18. Guidotti A., Konkel D. R., Ebstein B., Corda M. G., Wise B. C., Krutzsch H., Meek J. L., Costa E. Isolation, characterization, and purification to homogeneity of a rat brain protein (GABA-modulin). Proc. Natl. Acad. Sci. USA. 79:1982;6084-6088.
19. Hauw J. J., Boutry J. M., Sun P., Sazdovitch V., Duyckaerts C. Effects of vigabatrin and of GABA on myelinated rat cerebellar cultures: Preliminary data. Br. J. Clin. Pharmacol. 27:1989;S47-S52.
20. Jackson G. D., Williams S. R., Weller R. O., Van Bruggen N., Preece N. E., Williams S. C., Butler W. H., Duncan J. S. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res. 18:1994;57-66.
21. Jacobson S. Sequence of myelinization in the brain of the albino rat. A. Cerebral cortex, thalamus and related structures. J. Comp. Neurol. 121:1963;5-29.
22. Krogh C. M. E. Compendium of Pharmaceuticals and Specialties. 1995;Canadian Pharmaceutical Association, Ottawa. p. 1201-1202.
23. Lee M., Sakatani K., Young W. A role of GABA(A) receptors in hypoxia-induced conduction failure of neonatal rat spinal dorsal column axons. Brain Res. 601:1993;14-19.
24. Levine S. M., Wong D., Macklin W. B. Developmental expression of proteolipid protein and DM20 mRNAs and proteins in the rat brain. Dev. Neurosci. 12:1990;235-250.
25. Lim J. Y., Utz-Schneider D. A., Sakatani K., Kocsis J. D. The attenuation of GABA sensitivity in the maturing myelin-deficient rat optic nerve. Dev. Brain Res. 72:1993;15-20.
26. Liske S., Morris M. E. Effects of GABA, THIP, and potassium on excitability of myelinated axons of isolated amphibian spinal roots. Can. J. Physiol. Pharmacol. 67:1989;682-685.
27. Morgane P. J., Austin-LaFrance R., Bronzino J., Tonkiss J., Diaz-Cintra S., Cintra L., Kemper T., Galler J. R. Prenatal malnutrition and development of the brain. Neurosci. Biobehav. Rev. 17:1993;91-128.
28. Mumford J. P., Cannon D. J. Vigabatrin. Epilepsia. 35:1994;S25-S28.
29. Persson L. I., Ronnback L., Ben-Menachem E., Eriksson P., Nilsson M. Changes in CSF and brain soluble proteins following vigabatrin treatment in rats. Br. J. Clin. Pharmacol. 27:1989;73S-77S.
30. Riekkinen P. J., Pitkanen A., Ylinen A., Sivenius J., Halonen T. Specificity of vigabatrin for the GABAergic system in human epilepsy. Epilepsia. 30:1989;S18-S22.
31. Shuaib A., Murabit M. A., Kanthan R., Howlett W., Wishart T. The neuroprotective effects of gamma-vinyl GABA in transient global ischemia: A morphological study with early and delayed evaluations. Neurosci. Lett. 204:1996;1-4.
32. Uldall P., Alving J., Gram L., Hogenhaven H. Vigabatrin in childhood epilepsy: A 5-year follow-up study. Neuropediatrics. 26:1995;253-256.
33. Vaccarino F., Conti Tronconi B. M., Panula P., Guidotti A., Costa E. GABA-modulin: A synaptosomal basic protein that differs from small myelin basic protein of rat brain. J. Neurochem. 44:1985;278-290.
34. Weiss K. L., Schroeder C. E., Kastin S. J., Gibson J. P., Yarrington J. T., Heydorn W. E., McBride R. G., Sussman N. M., Arezzo J. C. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology. 44:1994;1944-1949.
35. Yarrington J. T., Gibson J. P., Dillberger J. E., Hurst G., Lippert B., Sussman N. M., Heydorn W. E., Marler R. J. Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor. Toxicol. Pathol. 21:1993;480-489.